Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004223 · ClinicalTrials.gov registry record · Phase 2
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
A Phase 2 study of Bladder Cancer and Urethral Cancer, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00004223: Completed Phase 2 study of Bladder Cancer and Urethral Cancer, sponsored by Eastern Cooperative Oncology Group.
NCT00004223 is a Phase 2 study of Bladder Cancer and Urethral Cancer that has completed, run by Eastern Cooperative Oncology Group. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004223, a Phase 2 study of Bladder Cancer and Urethral Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of docetaxel and gemcitabine in treating patients who have progressive regional or metastatic bladder cancer.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG gemcitabine hydrochloride
Study Locations (20)
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
- Veterans Affairs Medical Center - Lakeside Chicago - Chicago
- CCOP - Central Illinois - Decatur
- CCOP - Evanston - Evanston
- CCOP - Illinois Oncology Research Association - Peoria
- CCOP - Carle Cancer Center - Urbana
California
- Cancer Center and Beckman Research Institute, City of Hope - Duarte
- Veterans Affairs Medical Center - Palo Alto - Palo Alto
- Stanford University Medical Center - Stanford
Florida
- Veterans Affairs Medical Center - Gainsville - Gainesville
- Veterans Affairs Medical Center - Tampa (Haley) - Tampa
Georgia
- Emory University Hospital - Atlanta - Atlanta
- Veterans Affairs Medical Center - Atlanta (Decatur) - Decatur
Indiana
- Indiana University Cancer Center - Indianapolis
- Veterans Affairs Medical Center - Indianapolis (Roudebush) - Indianapolis
Arizona
- CCOP - Scottsdale Oncology Program - Scottsdale
Colorado
- CCOP - Colorado Cancer Research Program, Inc. - Denver
Delaware
- CCOP - Christiana Care Health Services - Wilmington
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-02-24 |
| Phase | Phase 2 |
What the finished NCT00004223 record still lists
NCT00004223 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 3 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.
NCT00004223 names 20 study sites across 10 states, led by Illinois, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00004223 about?
NCT00004223 is a clinical study titled "Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of docetaxel and gemcitabine in treating patients who have progressive r...
What is the current status of trial NCT00004223?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-02-24.
What conditions does trial NCT00004223 study?
This clinical trial studies the following conditions: Bladder Cancer, Urethral Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter.
What interventions are being tested in trial NCT00004223?
The interventions under investigation include: docetaxel (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00004223?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004223 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI